Latest news : Gamida Cell Ltd.

27/05/25	Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	CI
22/07/24	HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO	MT
18/06/24	Gamida Cell Names Rory Nealon as Chief Financial Officer	CI
18/06/24	Gamida Cell Names Sheila Frame as Chief Commercial Officer	CI
18/06/24	Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer	CI
18/06/24	Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC	CI
24/05/24	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
10/04/24	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
05/04/24	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI
29/03/24	Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	MT
28/03/24	Top Premarket Decliners	MT
28/03/24	Top Midday Decliners	MT
28/03/24	Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	MT

More news

Analysts' recommendations: Gamida Cell Ltd.

30/01/24	JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	MT
16/11/23	Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	MT
15/11/23	HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	MT
19/05/23	JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating	MT
16/05/23	Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating	MT

More recommendations

Press Releases: Gamida Cell Ltd.

27/03/24	Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management	AQ
27/03/24	Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update	AQ
22/03/24	Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results	AQ
24/02/24	Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	AQ
29/01/24	Gamida Cell Actively Pursuing Strategic Alternatives	AQ

More press releases

Managers and Directors: Gamida Cell Ltd.

Manager	Title	Age	Since
Joe Wiley CEO	Chief Executive Officer	55	-
Heayoung Shin CTO	Chief Tech/Sci/R&D Officer	-	01/06/2021
Rory Nealon COO	Chief Operating Officer	58	24/05/2024

Director	Title	Age	Since
Joe Wiley CHM	Chairman	55	-
George Hampton BRD	Director/Board Member	56	01/04/2019

More insiders

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The Company's clinical pipeline products include: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Employees

147

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - OTC Markets 02:54:51 25/05/24 am AEST			5-day change	1st Jan Change
0.0170 ^USD	+2.41%		-.--%	-

Market Cap	2.62M 2.26M 2.13M 1.93M 3.64M 251M 3.69M 24.96M 9.78M 125M 9.83M 9.62M 418M	P/E 2022	-1.04x	P/E 2023	-0.72x
Enterprise Value	39.01M 33.69M 31.7M 28.81M 54.19M 3.74B 54.98M 372M 146M 1.87B 146M 143M 6.23B	EV / Sales 2022	-	EV / Sales 2023	51,081,230x
Free-Float	89.41%	Yield 2022 *	-	Yield 2023	-

3 years	0.01	1.28
5 years	0.01	4.96
10 years	0.01	15.41

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/1/24	Ronit Simantov	Free	Chief Technology Officer	480,319	0.3621%
31/1/24	Ivan Borrello	Free	Director	200,000	0.1508%
31/1/24	Kenneth Moch	Free	Director	200,000	0.1508%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GAMIDA CELL LTD.	+2.41%	-.--%	-.--%	-98.60%	2.62M
WUXI APPTEC CO., LTD.	+0.17%	+4.35%	+72.39%	+114.97%	73.45B
ARGENX SE	+1.73%	+16.15%	+51.73%	+93.89%	62.99B
INSMED INCORPORATED	+0.11%	-3.10%	+0.94%	+491.16%	28.05B
WUXI BIOLOGICS (CAYMAN) INC.	-1.69%	+4.51%	+60.38%	+20.00%	25.42B
BIONTECH SE	+1.26%	-0.05%	-17.59%	-15.96%	23.3B
GENMAB A/S	0.00%	+5.57%	+39.57%	-14.30%	19.45B
PHARMAESSENTIA CORPORATION	-0.71%	-4.11%	+243.99%	+423.83%	18.16B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.59%	-1.04%	+14.69%	+515.29%	16.53B
EXELIXIS, INC.	+1.53%	+3.49%	+40.68%	+151.75%	13.16B
Average	+0.12%	+2.71%	+50.68%	+168.21%	28.05B
Weighted average by Cap.	+0.21%	+4.97%	+55.99%	+164.73%

Gamida Cell Ltd. Stock

Stocks

GMDA

IL0011552663

Biotechnology & Medical Research

Valuation: Gamida Cell Ltd.

Latest news : Gamida Cell Ltd.

Analysts' recommendations: Gamida Cell Ltd.

Press Releases: Gamida Cell Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Gamida Cell Ltd.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

	2022	2023
Net sales	-	1.78 1.54 1.45 1.32 2.48 170.93 2.51 17.01 6.66 85.49 6.7 6.55 284.76
Net income	-79.38M -68.56M -64.5M -58.62M -110M -7.61B -112M -757M -297M -3.8B -298M -292M -12.67B	-63M -54.41M -51.19M -46.53M -87.51M -6.04B -88.79M -600M -235M -3.02B -237M -231M -10.06B
Net Debt	39.31M 33.95M 31.94M 29.03M 54.6M 3.77B 55.4M 375M 147M 1.88B 148M 144M 6.27B	36.39M 31.43M 29.57M 26.88M 50.55M 3.49B 51.29M 347M 136M 1.74B 137M 134M 5.81B